admin, Author at PsyNews.com

Home Authors Posts by admin

2176 POSTS 0 COMMENTS

https://psynews.com

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday,...

Silo Pharma Announces Expansion of Intellectual Property Portfolio

Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding...

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program...

Psychedelic Therapies: From Approvals to Access

Making “Access” A Meaningful Part of Every Conversation about Psychedelic Therapy

The Agenda for Economic Analyses of Psychedelic-assisted Therapy

A Perspective on Providers: Scaling PAT in a Time of Therapist...

Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential...

Small Pharma Announces Update on Intellectual Property Portfolio with Two New...

1...909192...218 Page 91 of 218

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin